Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 5/2007

01-05-2007 | Article

The relationship between ACE genotype and risk of severe hypoglycaemia in a large population-based cohort of children and adolescents with type 1 diabetes

Authors: M. K. Bulsara, C. D. J. Holman, F. M. van Bockxmeer, E. A. Davis, P. H. Gallego, J. P. Beilby, L. J. Palmer, C. Choong, T. W. Jones

Published in: Diabetologia | Issue 5/2007

Login to get access

Abstract

Aims/hypothesis

Genetic factors may account for familial clustering related to diabetes complications. Studies have shown a significant relationship between the presence of the deletion (D) allele of the gene encoding ACE and risk of severe hypoglycaemia. This large prospective cohort study assesses this relationship in a large sample of children and adolescents with type 1 diabetes.

Subjects and methods

We studied 585 children and adolescents (mean age 11.9 ± 4 years, 48.4% males). The frequency of severe hypoglycaemia (an event leading to loss of consciousness or seizure) was prospectively assessed over the 13-year period 1992–2004. Patients were seen with their parents every 3 months and data recorded at each visit. The ACE gene was detected using PCR.

Results

In our cohort of 585 children, 186 (31.8%) had at least one episode of severe hypoglycaemia, and of these 28.0% had the II genotype, 48.9% had the ID genotype and 23.1% had the DD genotype. This was in agreement with the Hardy–Weinberg proportion. A total of 477 severe hypoglycaemic episodes was recorded with a total of 3,404 person-years of follow-up, giving a total incidence of 14 per 100 patient-years. No significant increase in risk for DD genotype (incidence rate ratio = 0.97, 95% CI 0.61–1.55) relative to II genotype was observed.

Conclusions/interpretation

This large prospective study concludes that the presence of the D allele of the ACE gene does not predict a significantly higher risk of severe hypoglycaemia in type 1 diabetic children and adolescents.
Literature
1.
Jones TW, Davis EA (2003) Hypoglycemia in children with type 1 diabetes: current issues and controversies. Pediatr Diabetes 4:143–150PubMedCrossRef
2.
Bulsara MK, Holman CDAJ, Davis EA, Jones TW (2004) The Impact of a decade of changing treatment on rates of severe hypoglycemia in a population-based cohort of children with type 1 diabetes. Diabetes Care 27:2293–2298PubMedCrossRef
3.
Cryer PE (2002) Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II Diabetes. Diabetologia 45:937–948PubMedCrossRef
4.
Sovik O, Thordarson H (1999) Dead-in-bed syndrome in young diabetic patients. Diabetes Care 22(Suppl 2):B40–B42PubMed
5.
Cryer PE (2005) Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes 54:3592–3601PubMedCrossRef
6.
Bulsara MK, Holman CDJ, Davis EA, Jones TW (2004) Evaluating risk factors associated with severe hypoglycaemia in epidemiology studies—what method should we use? Diabetic Medicine 21:914–919PubMedCrossRef
7.
The Diabetes Control and Complications Trial (DCCT), Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group (1997) Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes 46:1829–1839CrossRef
8.
Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S, Hougaard P, Thorsteinsson B (2003) Prediction of severe hypoglycaemia by angiotensin-converting enzyme activity and genotype in Type 1 Diabetes. Diabetologia 46:89–96PubMed
9.
Herings RMC, de Boer A, Leufkens HGM, Porsius A, Stricker BHC (1995) Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 345:1195–1198PubMedCrossRef
10.
Morris A, Boyle D, McMahon A et al (1997) ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes. DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside, Scotland. Medicines Monitoring Unit. Diabetes Care 20:1363–1367PubMedCrossRef
11.
van Haeften TW, Kong N, Bates A et al (1995) ACE inhibitors and hypoglycaemia. Lancet 346:125–127PubMedCrossRef
12.
Petrie J, Morris A, Ueda S et al (1995) Do ACE inhibitors improve insulin sensitivity? Lancet 346:583–584PubMedCrossRef
13.
Strachan M, Frier B (1998) Risk of severe hypoglycemia in diabetes patients taking ACE inhibitors. Diabetes Care 21:470PubMedCrossRef
14.
Chaturvedi N, Fuller J (1998) ACE inhibitors and risk of hypoglycemia in people with diabetes. Diabetes Care 21:470–472PubMedCrossRef
15.
Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F (1990) An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86:1343–1346PubMed
16.
Morris BJ, Zee RYL, Schrader AP (1994) Different frequencies of angiotensin-converting enzyme genotypes in older hypertensive individuals. J Clin Invest 94:1085–1089PubMedCrossRef
17.
Gayagay G, Yu B, Hambly B et al (1998) Elite endurance athletes and the ACE I allele—the role of genes in athletic performance. Hum Genet 103:48–50PubMedCrossRef
18.
Montgomery HE, Marshall R, Hemingway H et al (1998) Human gene for physical performance. Nature 393:221–222PubMedCrossRef
19.
Taylor RR, Mamotte CDS, Fallon K, van Bockxmeer FM (1999) Elite athletes and the gene for angiotensin-converting enzyme. J Appl Physiol 87:1035–1037PubMed
20.
Nordfeldt S, Samuelsson U (2003) Serum ACE predicts severe hypoglycemia in children and adolescents with type 1 diabetes. Diabetes Care 26:274–278PubMedCrossRef
21.
Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S, Hougaard P, Thorsteinsson B (2001) Activity of angiotensin-converting enzyme and risk of severe hypoglycaemia in type 1 diabetes mellitus. Lancet 357:1248–1253PubMedCrossRef
22.
Davis EA, Keating B, Byrne GC, Russell M, Jones TW (1997) Hypoglycemia: incidence and clinical predictors in a large population-based sample of children and adolescents with IDDM. Diabetes Care 20:22–25PubMedCrossRef
23.
Haynes A, Bower C, Bulsara MK, Jones TW, Davis EA (2004) Continued increase in the incidence of childhood Type 1 diabetes in a population-based Australian sample (1985–2002). Diabetologia 47:866–870PubMedCrossRef
24.
Haynes A, Bulsara MK, Bower C, Codde JP, Jones TW, Davis EA (2006) Independent effects of socioeconomic status and place of residence on the incidence of childhood type 1 diabetes in Western Australia. Pediatr Diabetes 7:94–100PubMedCrossRef
25.
Miller SA, Dykes DD, Polesky HF (1998) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215CrossRef
26.
Rigat B, Hubert C, Corvol P, Soubrier R (1992) PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 20:1433PubMedCrossRef
27.
Shanmugam V, Sell KW, Saha BK (1993) Mistyping ACE heterozygotes. PCR Methods Appl 3:120–121PubMed
28.
29.
Craig ME, Handelsman P, Donaghue KC et al (2002) Predictors of glycaemic control and hypoglycaemia in children and adolescents with type 1 diabetes from NSW and the ACT. Med J Aust 177:235–238PubMed
30.
Rewers A, Chase HP, Mackenzie T et al (2002) Predictors of acute complications in children with type 1 diabetes. JAMA 287:2511–2518PubMedCrossRef
31.
Tiret L, Rigat B, Visvikis S et al (1992) Evidence, from combined segregation and linkage analysis, that a variant of the Angiotensin I-converting Enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 51:197–205PubMed
32.
van Bockxmeer FM, Mamotte CDS, Burke V (2000) Angiotensin-converting enzyme gene polymorphism and premature coronary heart disease. Clin Sci 99:247–251PubMedCrossRef
33.
Bloem LJ, Manatunga AK, Pratt JH (1996) Racial difference in the relationship of Angiotensin I-coverting enzyme gene polymorphism to serum Angiotensin I-converting enzyme activity. Hypertension 27:62–66PubMed
34.
Crisan D, Carr J (2000) Angiotensin I-converting enzyme: genotype and disease associations. J Mol Diagn 2:105–115PubMed
35.
Morris BJ (1996) Hypothesis: An Angiotensin converting enzyme gentotype, present in one in three Caucasians, is associated with an increased mortality rate. Clin Exp Pharmacol Physiol 23:1–10PubMed
36.
Geddes J, Zammitt NN, Warren RE, Ashby PJ, Deary IJ, Frier BM (2006) Does serum angiotensin converting enzyme (ACE) concentration predict risk of severe hypoglycemia in type 1 diabetes? American Diabetes Association Scientific Conference, Washington DC, USA
37.
Holstein A, Plaschke A, Böttcher Y, Stumvoll M, Kovacs P (2006) The insertion/deletion polymorphism in the angiotensin-converting enzyme gene and hypoglycemia awareness in patients with type 1 Diabetes. Horm Metab Res 38:603–606PubMedCrossRef
Metadata
Title
The relationship between ACE genotype and risk of severe hypoglycaemia in a large population-based cohort of children and adolescents with type 1 diabetes
Authors
M. K. Bulsara
C. D. J. Holman
F. M. van Bockxmeer
E. A. Davis
P. H. Gallego
J. P. Beilby
L. J. Palmer
C. Choong
T. W. Jones
Publication date
01-05-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 5/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-007-0613-4

Other articles of this Issue 5/2007

Diabetologia 5/2007 Go to the issue

Article

In utero undernutrition reduces diabetes incidence in non-obese diabetic mice

Letter

Response to comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulphonylureas and metformin. Diabetologia 49:930–936

Article

Effect of a novel non-thiazolidinedione peroxisome proliferator-activated receptor α/γ agonist on glucose uptake

Article

Cortisol clearance and associations with insulin sensitivity, body fat and fatty liver in middle-aged men

Meta-Analysis

Metabolic effects of interventions to increase exercise in adults with type 2 diabetes

Article

Prospective prediction of spontaneous but not recurrent autoimmune diabetes in the non-obese diabetic mouse
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits